Isolation of non-embryonic stem cells and uses thereof
US-2016237400-A1 · Aug 18, 2016 · US
US9828583B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9828583-B2 |
| Application number | US-201314371627-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jan 11, 2013 |
| Priority date | Jan 13, 2012 |
| Publication date | Nov 28, 2017 |
| Grant date | Nov 28, 2017 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Provided herein are methods and compositions relating, in part, to the generation of human progenitor cells committed to the lung lineage and uses of such cells for treatment of lung diseases/disorders or injury to the lung. Whether an adult stem cell can be isolated from human adult lung remains controversial in the art and at present, methods for isolating and using adult lung stem cells from humans lack reproducibility. Thus, the methods and compositions described herein are advantageous over the present state of knowledge in the art and permit the generation of human lung progenitor cells for treatment, tissue engineering, and screening assays.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising an isolated and viable human Nkx2.1 positive, Sox2 positive proximal airway multipotent progenitor cell and a decellularized adult human lung scaffold, wherein the proximal airway multipotent progenitor cell is committed to the lung lineage. 2. The composition of claim 1 , wherein the cell is Tuj1 negative and Pax8 negative. 3. The composition of claim 1 , wherein the cell is proliferative and differentiates into an airway basal stem cell, a ciliated cell, a Clara cell, a neuroendocrine cell, or a squamous epithelial cell under chosen differentiation conditions. 4. The composition of claim 1 , wherein the scaffold is implantable in a subject. 5. The composition of claim 1 , wherein the scaffold is biodegradable. 6. The composition of claim 1 , wherein the progenitor cell is not isolated from an embryo, an embryonic stem cell or other cell derived in culture from an embryo.
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for disorders of the respiratory system · CPC title
Transforming growth factor beta (TGF-β) · CPC title
Materials at least partially resorbable by the body · CPC title
Stem cells; Progenitors · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.